Blood

• 

  Publication Venue For

  • A Single-cell Atlas Identifies Pretreatment Features of Primary Imatinib Resistance in Chronic Myeloid Leukemia. 2023
  • How I Treat Anemia in Older Adults. 2023
  • Hydroxyurea for secondary stroke prevention in children with sickle cell anemia in Nigeria: a randomized controlled trial..  141:825-834. 2023
  • BRAF-negative, CD103-negative hairy cell leukemia..  141:806. 2023
  • Composite ALK-negative anaplastic large-cell lymphoma and mantle cell lymphoma..  141:556. 2023
  • A randomized clinical trial of the efficacy and safety of rivipansel for sickle cell vaso-occlusive crisis..  141:168-179. 2023
  • A randomized trial of blood donor iron repletion on red cell quality for transfusion and donor cognition and well-being..  140:2730-2739. 2022
  • Prebiotic galactooligosaccharides interact with mouse gut microbiota to attenuate acute graft-versus-host disease..  140:2300-2304. 2022
  • Outcomes following treatment for ADA-deficient severe combined immunodeficiency: a report from the PIDTC..  140:685-705. 2022
  • The oral ferroportin inhibitor vamifeport improves hemodynamics in a mouse model of sickle cell disease..  140:769-781. 2022
  • Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment..  140:630-643. 2022
  • Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC..  140:419-437. 2022
  • COVID-19 convalescent plasma..  140:196-207. 2022
  • Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial..  140:112-120. 2022
  • Modifiable risk factors for neurocognitive and psychosocial problems after Hodgkin lymphoma..  139:3073-3086. 2022
  • A randomized phase 3 trial of interferon-α vs hydroxyurea in polycythemia vera and essential thrombocythemia..  139:2931-2941. 2022
  • Pure erythroid leukemia evolved from JAK2V617F-positive polycythemia vera: blast phase transformation along erythroid line..  139:2574. 2022
  • Chronic GVHD of the CNS..  139:1271-1272. 2022
  • Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib..  138:2810-2827. 2021
  • Complement mediates binding and procoagulant effects of ultralarge HIT immune complexes..  138:2106-2116. 2021
  • Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study..  138:1429-1440. 2021
  • Plasmablastic myeloma/leukemia variant of monomorphic posttransplant lymphoproliferative disorder..  138:1510. 2021
  • COVID-19 and VITT: same or different?.  138:1206-1207. 2021
  • A composite single-nucleotide polymorphism prediction signature for extranodal natural killer/T-cell lymphoma..  138:452-463. 2021
  • Vaccine-induced immune thrombotic thrombocytopenia: what we know and do not know..  138:293-298. 2021
  • Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT): What We Know and Don't Know. 2021
  • Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy..  137:2817-2826. 2021
  • Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma..  137:2621-2633. 2021
  • An effusion-based presentation of ALK- anaplastic large cell lymphoma..  137:2563. 2021
  • BAFF promotes heightened BCR responsiveness and manifestations of chronic GVHD after allogeneic stem cell transplantation..  137:2544-2557. 2021
  • ELIPSIS: developing tools to better understand VOC in SCD..  137:1987-1988. 2021
  • Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families..  137:2046-2056. 2021
  • MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis..  137:1615-1627. 2021
  • Fecal microbiota diversity disruption and clinical outcomes after auto-HCT: a multicenter observational study..  137:1527-1537. 2021
  • Isatuximab as monotherapy and combined with dexamethasone in patients with relapsed/refractory multiple myeloma..  137:1154-1165. 2021
  • Can HIT testing lose its radioactivity?.  137:1008-1010. 2021
  • Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia..  137:751-762. 2021
  • Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation: the BMT CTN 1101 trial..  137:420-428. 2021
  • Catch those antibodies before they fall..  136:2489-2490. 2020
  • Glucagon-like peptide 2 for intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans..  136:1442-1455. 2020
  • I have a gut feeling…..  136:1380. 2020
  • Meningeosis myelomatosis..  136:1466. 2020
  • Outcomes of COVID-19 in patients with CLL: a multicenter international experience..  136:1134-1143. 2020
  • Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). 2020
  • Earlier the better: convalescent plasma..  136:652-654. 2020
  • House calls for stem cell transplant patients during the COVID-19 pandemic..  136:370-371. 2020
  • The microbe-derived short-chain fatty acids butyrate and propionate are associated with protection from chronic GVHD..  136:130-136. 2020
  • An integrative model of pathway convergence in genetically heterogeneous blast crisis chronic myeloid leukemia..  135:2337-2353. 2020
  • Stage I-II nodular lymphocyte-predominant Hodgkin lymphoma: a multi-institutional study of adult patients by ILROG..  135:2365-2374. 2020
  • EPCR knockout: inflaming the discussion..  135:2201-2202. 2020
  • Recognition of PF4-VWF complexes by heparin-induced thrombocytopenia antibodies contributes to thrombus propagation..  135:1270-1280. 2020
  • Fc-modified HIT-like monoclonal antibody as a novel treatment for sepsis..  135:743-754. 2020
  • Red blood cell microvesicles activate the contact system, leading to factor IX activation via 2 independent pathways..  135:755-765. 2020
  • The efficacy-toxicity conundrum: breaking the mold..  135:704-706. 2020
  • Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia..  135:463-471. 2020
  • Arterial thrombosis and second cancer in MPNs..  135:301-302. 2020
  • Introduction to a review series on treatment of venous thrombotic disorders..  135:299-300. 2020
  • Coactivation of NF-κB and Notch signaling is sufficient to induce B-cell transformation and enables B-myeloid conversion..  135:108-120. 2020
  • Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial..  134:33. 2019
  • Understanding How Fc-Modification Transforms a Pathogenic Heparin-Induced Thrombocytopenia (HIT)-like Monoclonal Antibody into a Novel Treatment for Sepsis..  134:10. 2019
  • Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma..  134:19. 2019
  • The whole-genome landscape of Burkitt lymphoma subtypes..  134:1598-1607. 2019
  • Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea..  134:1498-1509. 2019
  • Inherited genetic susceptibility to acute lymphoblastic leukemia in Down syndrome..  134:1227-1237. 2019
  • Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J, Müller A, Pachynski R, Czerwinski D, Coutre S, Chao MP, Chen L, Tedder TF, Levy R. CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood. 2011;117(8):2423-2432..  134:658. 2019
  • Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy..  134:44-58. 2019
  • Red blood cells: beyond the transfusion..  133:2627-2628. 2019
  • Peripheral serotonin causes dengue virus-induced thrombocytopenia through 5HT2 receptors..  133:2325-2337. 2019
  • Noninfectious transfusion-associated adverse events and their mitigation strategies..  133:1831-1839. 2019
  • Serum levels of TARC, MDC, IL-10, and soluble CD163 in Hodgkin lymphoma: a SWOG S0816 correlative study..  133:1762-1765. 2019
  • A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403..  133:1548-1559. 2019
  • How I treat refractory chronic graft-versus-host disease..  133:1191-1200. 2019
  • Bad weed: synthetic cannabinoid-associated coagulopathy..  133:902-905. 2019
  • Novel susceptibility variants at the ERG locus for childhood acute lymphoblastic leukemia in Hispanics..  133:724-729. 2019
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases..  133:754-762. 2019
  • Introduction to a review series on new therapeutics for inherited and acquired bleeding conditions..  133:383-384. 2019
  • Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma..  132:2546-2554. 2018
  • Polyreactive IgM initiates complement activation by PF4/heparin complexes through the classical pathway..  132:2431-2440. 2018
  • Notch signaling mediated by Delta-like ligands 1 and 4 controls the pathogenesis of chronic GVHD in mice..  132:2188-2200. 2018
  • Neoplastic plasma cells with azurophilic crystalline inclusions mimicking promyelocytes..  132:1999. 2018
  • B-cell receptor-mediated NFATc1 activation induces IL-10/STAT3/PD-L1 signaling in diffuse large B-cell lymphoma..  132:1805-1817. 2018
  • SCID genotype and 6-month posttransplant CD4 count predict survival and immune recovery..  132:1737-1749. 2018
  • A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML..  132:1125-1133. 2018
  • CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET..  132:1013-1021. 2018
  • Dynamic intercellular redistribution of HIT antigen modulates heparin-induced thrombocytopenia..  132:727-734. 2018
  • Transfusion dependence, use of hospice services, and quality of end-of-life care in leukemia..  132:717-726. 2018
  • B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation..  131:2967-2977. 2018
  • Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies..  131:2782-2788. 2018
  • Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis..  131:2541-2551. 2018
  • Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study..  131:2183-2192. 2018
  • Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy..  131:1704-1711. 2018
  • B-cell targeting in chronic graft-versus-host disease..  131:1399-1405. 2018
  • Pevonedistat, a first-in-class NEDD8-activating enzyme inhibitor, combined with azacitidine in patients with AML..  131:1415-1424. 2018
  • A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia..  131:387-396. 2018
  • PD-1 expression and clinical PD-1 blockade in B-cell lymphomas..  131:68-83. 2018
  • Immune reconstitution and survival of 100 SCID patients post-hematopoietic cell transplant: a PIDTC natural history study..  130:2718-2727. 2017
  • Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2..  130:2682-2688. 2017
  • Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma..  130:2401-2409. 2017
  • Carcinocythemia (carcinoma cell leukemia)..  130:2357. 2017
  • An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD..  130:2131-2145. 2017
  • Adult high-grade B-cell lymphoma with Burkitt lymphoma signature: genomic features and potential therapeutic targets..  130:1819-1831. 2017
  • Relapse of an acute leukemia of mixed lineage as an isolated orbital mass..  130:953. 2017
  • Intracranial hemorrhage in patients with atrial fibrillation receiving anticoagulation therapy..  129:2980-2987. 2017
  • Heparin-induced thrombocytopenia..  129:2864-2872. 2017
  • More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia..  129:2584-2587. 2017
  • Eliglustat maintains long-term clinical stability in patients with Gaucher disease type 1 stabilized on enzyme therapy..  129:2375-2383. 2017
  • Abnormal joint and bone wound healing in hemophilia mice is improved by extending factor IX activity after hemarthrosis..  129:2161-2171. 2017
  • Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era..  129:1763-1767. 2017
  • Clinical and pathological characteristics of HIV- and HHV-8-negative Castleman disease..  129:1658-1668. 2017
  • In utero cytomegalovirus infection and development of childhood acute lymphoblastic leukemia..  129:1680-1684. 2017
  • Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation..  129:1548-1556. 2017
  • Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma..  128:3083-3100. 2016
  • An oxidative stress-based mechanism of doxorubicin cytotoxicity suggests new therapeutic strategies in ABC-DLBCL..  128:2797-2807. 2016
  • Phase 1 trial of rituximab, lenalidomide, and ibrutinib in previously untreated follicular lymphoma: Alliance A051103..  128:2510-2516. 2016
  • Hepatosplenic T-cell lymphoma with blastoid morphology in a patient with Crohn disease..  128:2275. 2016
  • The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21)..  128:1789-1799. 2016
  • Allogeneic bone marrow transplantation for treatment of severe hemolytic anemia attributable to hexokinase deficiency..  128:735-737. 2016
  • Progress toward less toxic conditioning..  128:322-323. 2016
  • GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo..  127:2723-2731. 2016
  • Development and validation of a rapid, aldehyde dehydrogenase bright-based cord blood potency assay..  127:2346-2354. 2016
  • Antibodies are back for thymic attack in cGVHD..  127:2170-2171. 2016
  • Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms..  127:1886-1895. 2016
  • Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure..  127:1656-1665. 2016
  • Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease..  127:810-819. 2016
  • Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma..  126:2284-2290. 2015
  • Platelets promote pulmonary pull of polys..  126:2174-2175. 2015
  • How I treat catastrophic thrombotic syndromes..  126:1285-1293. 2015
  • MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice..  126:1314-1323. 2015
  • Wnts are dispensable for differentiation and self-renewal of adult murine hematopoietic stem cells..  126:1086-1094. 2015
  • Improved outcomes associated with hematopoietic stem cell transplantation for patients with juvenile myelomonocytic leukemia..  126:561-562. 2015
  • Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease..  125:4085-4094. 2015
  • CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRβ repertoire..  125:3835-3850. 2015
  • Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use..  125:2656-2664. 2015
  • Crucial role for the VWF A1 domain in binding to type IV collagen..  125:2297-2304. 2015
  • Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study..  125:2164-2172. 2015
  • Aberrant B-cell homeostasis in chronic GVHD..  125:1703-1707. 2015
  • Liberation of ATP secondary to hemolysis is not mutually exclusive of regulated export..  125:1844-1845. 2015
  • A natural choice for hemophilia B..  125:1509-1510. 2015
  • Early HSCT corrects the skeleton in MPS..  125:1518-1519. 2015
  • Acute myeloid leukemia ontogeny is defined by distinct somatic mutations..  125:1367-1376. 2015
  • Red cells from ferrochelatase-deficient erythropoietic protoporphyria patients are resistant to growth of malarial parasites..  125:534-541. 2015
  • Genetic dissection of leukemia-associated IDH1 and IDH2 mutants and D-2-hydroxyglutarate in Drosophila..  125:336-345. 2015
  • Preclinical efficacy of MEK inhibition in Nras-mutant AML..  124:3947-3955. 2014
  • Management and clinical outcomes in patients treated with apixaban vs warfarin undergoing procedures..  124:3692-3698. 2014
  • A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients..  124:2921-2929. 2014
  • Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation..  124:2596-2606. 2014
  • Ser70 phosphorylation of Bcl-2 by selective tyrosine nitration of PP2A-B56δ stabilizes its antiapoptotic activity..  124:2223-2234. 2014
  • A nonsense mutation in IKBKB causes combined immunodeficiency..  124:2046-2050. 2014
  • Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma..  124:1915-1925. 2014
  • Spotlight on pathogenesis of TRALI: HNA-3a (CTL2) antibodies..  124:1868-1872. 2014
  • How I treat sinusoidal obstruction syndrome..  123:4023-4026. 2014
  • Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans..  123:3988-3998. 2014
  • Bye-bye TRALI: by understanding and innovation..  123:3374-3376. 2014
  • The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells..  123:2988-2996. 2014
  • Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms..  123:2645-2651. 2014
  • The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia..  123:2497-2503. 2014
  • Increased BCR responsiveness in B cells from patients with chronic GVHD..  123:2108-2115. 2014
  • Distinct functional programming of human fetal and adult monocytes..  123:1897-1904. 2014
  • The polyphony of BACH2..  123:950. 2014
  • Amino acid substitution at peptide-binding pockets of HLA class I molecules increases risk of severe acute GVHD and mortality..  122:3651-3658. 2013
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia..  122:3432-3439. 2013
  • GATA3 risk alleles are associated with ancestral components in Hispanic children with ALL..  122:3385-3387. 2013
  • Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease..  122:3365-3375. 2013
  • Essential role of PR-domain protein MDS1-EVI1 in MLL-AF9 leukemia..  122:2888-2892. 2013
  • MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program..  122:2630-2640. 2013
  • PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma..  122:2683-2693. 2013
  • Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome..  122:2673-2682. 2013
  • Analysis of risk factors influencing outcomes after cord blood transplantation in children with juvenile myelomonocytic leukemia: a EUROCORD, EBMT, EWOG-MDS, CIBMTR study..  122:2135-2141. 2013
  • Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial..  122:1510-1517. 2013
  • Inhibiting inhibitory pathways in human γδ T cells..  122:857-858. 2013
  • EBV-positive diffuse large B-cell lymphoma of the elderly..  122:328-340. 2013
  • Gene-centric association study of acute chest syndrome and painful crisis in sickle cell disease patients..  122:434-442. 2013
  • A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia..  121:4854-4860. 2013
  • Adhesion to osteopontin in the bone marrow niche regulates lymphoblastic leukemia cell dormancy..  121:4821-4831. 2013
  • Novel childhood ALL susceptibility locus BMI1-PIP4K2A is specifically associated with the hyperdiploid subtype..  121:4808-4809. 2013
  • Single nucleotide variation in the TP53 3' untranslated region in diffuse large B-cell lymphoma treated with rituximab-CHOP: a report from the International DLBCL Rituximab-CHOP Consortium Program..  121:4529-4540. 2013
  • The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts..  121:4439-4442. 2013
  • MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program..  121:4021-4031. 2013
  • Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning..  121:3981-3987. 2013
  • Novel diagnostic assays for heparin-induced thrombocytopenia..  121:3727-3732. 2013
  • Critical role for mouse marginal zone B cells in PF4/heparin antibody production..  121:3484-3492. 2013
  • Donor-derived regulatory B cells are important for suppression of murine sclerodermatous chronic graft-versus-host disease..  121:3274-3283. 2013
  • Murine natural killer immunoreceptors use distinct proximal signaling complexes to direct cell function..  121:3135-3146. 2013
  • High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass..  121:2828-2835. 2013
  • CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study..  121:2715-2724. 2013
  • Genome-wide study of methotrexate clearance replicates SLCO1B1..  121:898-904. 2013
  • Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia..  121:752-758. 2013
  • How I treat thrombocytopenia in pregnancy..  121:38-47. 2013
  • Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation..  120:4873-4881. 2012
  • Perioperative management of patients on chronic antithrombotic therapy..  120:4699-4705. 2012
  • Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia..  120:4197-4204. 2012
  • HIT and run: heparin's unusual immune response..  120:4119-4120. 2012
  • Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study..  120:3986-3996. 2012
  • Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans..  120:3635-3646. 2012
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation..  120:2899-2908. 2012
  • B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways..  120:2529-2536. 2012
  • Meta-analysis of 2040 sickle cell anemia patients: BCL11A and HBS1L-MYB are the major modifiers of HbF in African Americans..  120:1961-1962. 2012
  • Single nucleotide polymorphisms and inherited risk of chronic lymphocytic leukemia among African Americans..  120:1687-1690. 2012
  • Dynamic antibody-binding properties in the pathogenesis of HIT..  120:1137-1142. 2012
  • Common variation at 6p21.31 (BAK1) influences the risk of chronic lymphocytic leukemia..  120:843-846. 2012
  • Further examination of BAFF SNPs in cGVHD..  120:700-701. 2012
  • miR-3151 interplays with its host gene BAALC and independently affects outcome of patients with cytogenetically normal acute myeloid leukemia..  120:249-258. 2012
  • WHIM syndrome caused by a single amino acid substitution in the carboxy-tail of chemokine receptor CXCR4..  120:181-189. 2012
  • CD62L- memory T cells enhance T-cell regeneration after allogeneic stem cell transplantation by eliminating host resistance in mice..  119:6344-6353. 2012
  • PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI..  119:5285-5293. 2012
  • Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning..  119:4133-4141. 2012
  • Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressure..  119:3684-3690. 2012
  • Regulation of mast cell survival and function by tuberous sclerosis complex 1..  119:3306-3314. 2012
  • Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function..  119:3113-3122. 2012
  • Heme induces programmed necrosis on macrophages through autocrine TNF and ROS production..  119:2368-2375. 2012
  • The endothelial protein C receptor (PROCR) Ser219Gly variant and risk of common thrombotic disorders: a HuGE review and meta-analysis of evidence from observational studies..  119:2392-2400. 2012
  • Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells..  119:e35-e44. 2012
  • Giving TRALI the one-two punch..  119:1620-1621. 2012
  • Mitochondrial dysfunction in ataxia-telangiectasia..  119:1490-1500. 2012
  • Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium..  119:1217-1227. 2012
  • Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras..  119:1032-1035. 2012
  • Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A..  119:238-250. 2012
  • Risk factors for acute GVHD and survival after hematopoietic cell transplantation..  119:296-307. 2012
  • ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category..  118:6920-6929. 2011
  • Warfarin and acetaminophen interaction: a summary of the evidence and biologic plausibility..  118:6269-6273. 2011
  • LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function..  118:5851-5861. 2011
  • Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia..  118:5914-5917. 2011
  • Mast cell modulation of the vascular and lymphatic endothelium..  118:5383-5393. 2011
  • Molecular dissection of the miR-17-92 cluster's critical dual roles in promoting Th1 responses and preventing inducible Treg differentiation..  118:5487-5497. 2011
  • "Sowing dragon's teeth?" Myeloma and AML..  118:4008-4009. 2011
  • Clofarabine and busulfan conditioning facilitates engraftment and provides significant antitumor activity in nonremission hematologic malignancies..  118:4258-4264. 2011
  • EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma..  118:4024-4035. 2011
  • SET oncoprotein overexpression in B-cell chronic lymphocytic leukemia and non-Hodgkin lymphoma: a predictor of aggressive disease and a new treatment target..  118:4150-4158. 2011
  • Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans..  118:3003-3012. 2011
  • Myeloid dysplasia and bone marrow hypocellularity in adenosine deaminase-deficient severe combined immune deficiency..  118:2688-2694. 2011
  • Irgm1 protects hematopoietic stem cells by negative regulation of IFN signaling..  118:1525-1533. 2011
  • Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS)..  118:1413-1420. 2011
  • miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy..  118:1034-1040. 2011
  • Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner..  118:368-379. 2011
  • Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group..  118:243-251. 2011
  • Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia..  117:7007-7013. 2011
  • Skeletal muscle hemojuvelin is dispensable for systemic iron homeostasis..  117:6319-6325. 2011
  • Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET..  117:5314-5320. 2011
  • Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection..  117:4805-4815. 2011
  • Tmprss6 is a genetic modifier of the Hfe-hemochromatosis phenotype in mice..  117:4590-4599. 2011
  • Negative regulation of mTOR activation by diacylglycerol kinases..  117:4022-4031. 2011
  • Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new..  117:3268-3276. 2011
  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse..  117:3294-3301. 2011
  • The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation..  117:3391-3401. 2011
  • What's up with 2 cord transplantation?.  117:3248-3249. 2011
  • ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes..  117:2441-2450. 2011
  • CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies..  117:2423-2432. 2011
  • Recovery of B-cell homeostasis after rituximab in chronic graft-versus-host disease..  117:2275-2283. 2011
  • Genome-wide association study identifies a novel susceptibility locus at 6p21.3 among familial CLL..  117:1911-1916. 2011
  • Transfusion-related acute lung injury: from bedside to bench and back..  117:1463-1471. 2011
  • Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells..  117:530-541. 2011
  • First use of thymus transplantation therapy for FOXN1 deficiency (nude/SCID): a report of 2 cases..  117:688-696. 2011
  • Regulation of steady-state neutrophil homeostasis by macrophages..  117:618-629. 2011
  • Transferrin is a major determinant of hepcidin expression in hypotransferrinemic mice..  117:630-637. 2011
  • A new guise for hyper-IgM syndrome..  116:5785-5786. 2010
  • Endogenous oncogenic Nras mutation promotes aberrant GM-CSF signaling in granulocytic/monocytic precursors in a murine model of chronic myelomonocytic leukemia..  116:5991-6002. 2010
  • Heparin modifies the immunogenicity of positively charged proteins..  116:6046-6053. 2010
  • BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study..  116:5660-5669. 2010
  • Hepcidin induction by transgenic overexpression of Hfe does not require the Hfe cytoplasmic tail, but does require hemojuvelin..  116:5679-5687. 2010
  • Progenitor cell dose determines the pace and completeness of engraftment in a xenograft model for cord blood transplantation..  116:5518-5527. 2010
  • Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation..  116:5111-5118. 2010
  • Acquired genomic copy number aberrations and survival in adult acute myelogenous leukemia..  116:4958-4967. 2010
  • Deep sequencing of the small RNA transcriptome of normal and malignant human B cells identifies hundreds of novel microRNAs..  116:e118-e127. 2010
  • American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer..  116:4045-4059. 2010
  • microRNA miR-144 modulates oxidative stress tolerance and associates with anemia severity in sickle cell disease..  116:4338-4348. 2010
  • FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study..  116:3622-3626. 2010
  • Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease..  116:3431-3434. 2010
  • Gemtuzumab ozogamicin: is there room for salvage?.  116:2618-2619. 2010
  • Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia..  116:1761-1766. 2010
  • P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808..  116:1413-1421. 2010
  • Down syndrome childhood acute lymphoblastic leukemia has a unique spectrum of sentinel cytogenetic lesions that influences treatment outcome: a report from the Children's Oncology Group..  116:1045-1050. 2010
  • Pathway discovery in mantle cell lymphoma by integrated analysis of high-resolution gene expression and copy number profiling..  116:953-961. 2010
  • Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study..  116:788-792. 2010
  • Pulmonary hypertension and nitric oxide depletion in sickle cell disease..  116:687-692. 2010
  • Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia..  116:71-80. 2010
  • Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides induces an apoptotic pathway in human chronic lymphocytic leukemia B cells..  115:5041-5052. 2010
  • Akt1 and Akt2 promote peripheral B-cell maturation and survival..  115:4043-4050. 2010
  • Down-regulation of Bmp/Smad signaling by Tmprss6 is required for maintenance of systemic iron homeostasis..  115:3817-3826. 2010
  • Proinflammatory state, hepcidin, and anemia in older persons..  115:3810-3816. 2010
  • Successful treatment using omacetaxine for a patient with CML and BCR-ABL1 [corrected] 35INS..  115:3852. 2010
  • Hepatocyte-targeted HFE and TFR2 control hepcidin expression in mice..  115:3374-3381. 2010
  • Suppression of adaptive immune responses during primary SIV infection of sabaeus African green monkeys delays partial containment of viremia but does not induce disease..  115:3070-3078. 2010
  • Gfi-1B controls human erythroid and megakaryocytic differentiation by regulating TGF-beta signaling at the bipotent erythro-megakaryocytic progenitor stage..  115:2784-2795. 2010
  • Placenta growth factor in sickle cell disease: association with hemolysis and inflammation..  115:2014-2020. 2010
  • Fetal hemoglobin in sickle cell anemia: genome-wide association studies suggest a regulatory region in the 5' olfactory receptor gene cluster..  115:1815-1822. 2010
  • Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice..  114:5454-5463. 2009
  • How I treat ADA deficiency..  114:3524-3532. 2009
  • The antitumorigenic trifecta..  114:1727-1728. 2009
  • Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization..  114:1331-1339. 2009
  • Thymic output, T-cell diversity, and T-cell function in long-term human SCID chimeras..  114:1445-1453. 2009
  • Extranodal marginal zone lymphoma of the ocular adnexa..  114:501-510. 2009
  • The importance of Src homology 2 domain-containing leukocyte phosphoprotein of 76 kilodaltons sterile-alpha motif domain in thymic selection and T-cell activation..  114:74-84. 2009
  • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma..  113:6069-6076. 2009
  • Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma..  113:5720-5726. 2009
  • Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation..  113:5330-5339. 2009
  • Nothing typical about HIT..  113:4825-4826. 2009
  • Patterns of microRNA expression characterize stages of human B-cell differentiation..  113:4586-4594. 2009
  • Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain..  113:4250-4261. 2009
  • Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease..  113:3865-3874. 2009
  • Analysis of somatic hypermutation in X-linked hyper-IgM syndrome shows specific deficiencies in mutational targeting..  113:3706-3715. 2009
  • D-dimer antigen: current concepts and future prospects..  113:2878-2887. 2009
  • Endothelial progenitor cell infusion induces hematopoietic stem cell reconstitution in vivo..  113:2104-2107. 2009
  • Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes..  113:1768-1777. 2009
  • Oncogenic Kras-induced leukemogeneis: hematopoietic stem cells as the initial target and lineage-specific progenitors as the potential targets for final leukemic transformation..  113:1304-1314. 2009
  • An L-selectin ligand distinct from P-selectin glycoprotein ligand-1 is expressed on endothelial cells and promotes neutrophil rolling in inflammation..  112:4915-4923. 2008
  • Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice lacking Gimap5..  112:4905-4914. 2008
  • Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c..  112:4284-4291. 2008
  • Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies..  112:4318-4327. 2008
  • FVIIa: you've come a long way, baby!.  112:3002-3003. 2008
  • Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium..  112:3474-3483. 2008
  • Structural profiles of TP53 gene mutations predict clinical outcome in diffuse large B-cell lymphoma: an international collaborative study..  112:3088-3098. 2008
  • Analysis of the linker for activation of T cells and the linker for activation of B cells in natural killer cells reveals a novel signaling cassette, dual usage in ITAM signaling, and influence on development of the Ly49 repertoire..  112:2869-2877. 2008
  • Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes..  112:2979-2989. 2008
  • B lymphocytes: how they develop and function..  112:1570-1580. 2008
  • Genomic complexity identifies patients with aggressive chronic lymphocytic leukemia..  112:1993-2003. 2008
  • Hematopoietic-specific Stat5-null mice display microcytic hypochromic anemia associated with reduced transferrin receptor gene expression..  112:2071-2080. 2008
  • Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV..  112:1205-1213. 2008
  • PILAR is a novel modulator of human T-cell expansion..  112:1259-1268. 2008
  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines..  112:610-618. 2008
  • It really IS the red cell..  112:459-460. 2008
  • Forging a field: the golden age of iron biology..  112:219-230. 2008
  • Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study..  111:5477-5485. 2008
  • Identification of genetic polymorphisms associated with risk for pulmonary hypertension in sickle cell disease..  111:5721-5726. 2008
  • Radiologic and nuclear events: contingency planning for hematologists/oncologists..  111:5440-5445. 2008
  • Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study..  111:5515-5523. 2008
  • Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study..  111:5403-5410. 2008
  • Development and validation of a predictive model for chemotherapy-associated thrombosis..  111:4902-4907. 2008
  • Follicular lymphoma and the microenvironment..  111:4427-4428. 2008
  • How I use fibrinogen replacement therapy in acquired bleeding..  125:1387-1393. 2015
  • Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. 2014
  • PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma. 2013